Genmab Closes $2.5 Billion Notes Offering to Fund Merus Acquisition

Reuters12-04
Genmab Closes $2.5 Billion Notes Offering to Fund Merus Acquisition

Genmab A/S has completed the closing of a previously announced private offering, raising $1.5 billion through 6.250% senior secured notes due 2032 and $1.0 billion through 7.250% senior unsecured notes due 2033. The company plans to use the proceeds from this offering, along with funds from new credit facilities and cash on hand, to finance the pending acquisition of Merus N.V. and cover related fees and expenses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001142806-en) on December 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment